Glucompet

Glucompet is an injectable solution containing the radiopharmaceutical fludeoxyglucose (18F) at a standard clinical concentration. It is supplied as a prescription‑only product for intravenous administration in diagnostic imaging. The compound acts as a glucose analog that accumulates in metabolically active cells, enabling visualization with positron emission tomography (PET). Glucompet is marketed in the European Union for use in oncologic, neurologic, and cardiac routine PET studies.

Glucompet is employed in several PET imaging applications to assess tissue metabolism and guide clinical decision‑making.

- Oncology PET imaging for tumor detection, staging, and treatment monitoring. - Neurology PET imaging to evaluate cerebral glucose metabolism in disorders such as epilepsy, dementia, and brain tumors. - Cardiology PET imaging for myocardial viability and perfusion assessment. - Research studies investigating metabolic pathways and novel therapeutic agents. - Pediatric imaging when clinically indicated, following appropriate radiation safety guidelines.

Adverse reactions to Glucompet are generally related to the radiopharmaceutical nature of the agent and the intravenous route of administration.

Common: - Transient flushing or warmth sensation at the injection site. - Mild nausea or vomiting. - Temporary headache. - Short‑lasting dizziness or light‑headedness. - Low‑grade fever within 24 hours.

Serious: - Allergic reactions such as urticaria, bronchospasm, or anaphylaxis. - Severe hypotension or cardiovascular collapse. - Persistent vomiting or dehydration. - Radiation‑related skin erythema at the injection site (rare).

Use of Glucompet requires careful consideration of patient‑specific factors and adherence to radiation safety protocols.

- Verify pregnancy status; avoid use in pregnant patients unless benefits outweigh risks. - Assess renal function, as impaired clearance may affect tracer distribution. - Ensure adequate hydration before and after injection to facilitate tracer elimination. - Review concurrent medications that may alter glucose metabolism (e.g., insulin, glucocorticoids). - Follow institutional radiation protection guidelines for staff and environment. - Obtain informed consent describing radiation exposure and potential side effects. - Document patient’s fasting status, typically 4–6 hours prior to administration.

Glucompet may interact with other agents that influence glucose metabolism or compete for the same transport mechanisms.

Avoid: - High‑dose insulin or oral hypoglycemics administered shortly before the scan, which can reduce tracer uptake. - Radiopharmaceuticals that share the same PET imaging window (e.g., other 18F‑labeled compounds) administered within the same day.

Use with caution: - Intravenous contrast agents used for CT components of PET/CT, which may affect attenuation correction. - Medications affecting thyroid function, as altered metabolism can influence background activity. - Beta‑blockers or calcium channel blockers that modify myocardial perfusion in cardiac PET studies. - Anticonvulsants that alter cerebral glucose utilization.